Journal of Clinical Oncology, Vol 12, 1572-1576, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Randomized comparison of high-dose and low-dose intravenous interleukin- 2 for the therapy of metastatic renal cell carcinoma: an interim report

JC Yang, SL Topalian, D Parkinson, DJ Schwartzentruber, JS Weber, SE Ettinghausen, DE White, SM Steinberg, DJ Cole and HI Kim
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

PURPOSE: A randomized prospective study was performed to compare the efficacy and toxicity of high-dose intravenous bolus interleukin-2 (IL- 2) and a lower-dose intravenous bolus regimen for the treatment of metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Between March 1991 and April 1993, 125 patients with metastatic RCC were randomized to receive IL-2 by intravenous bolus every 8 hours at either 720,000 IU/kg (high-dose) or 72,000 IU/kg (low-dose) to the maximum- tolerated number of doses (or a maximum of 15 doses). After approximately 7 to 10 days, both treatment groups were re-treated with a second identical cycle of therapy. Those patients who were stable or responding to treatment 5 to 6 weeks later went on to receive re- treatment with another course (two cycles) of therapy. Response rates and toxicity were determined for the two treatment arms. RESULTS: One hundred twenty-five patients received a total of 208 courses of therapy. Sixty patients were randomized to receive low-dose, and 65 to receive high-dose IL-2. There were no treatment-related deaths in either arm. There was a greater incidence of grade III or IV thrombocytopenia, malaise, and hypotension in patients who received high-dose IL-2, while patients who received low-dose IL-2 had significantly more infections. Three percent of treatment courses with low-dose IL-2 required vasopressor support, compared with 52% of courses with high-dose IL-2. Patients who received low-dose IL-2 had a 7% complete response (CR) and an 8% partial response (PR) rate, and patients who received high-dose IL-2 had a 3% CR and a 17% PR rate. CONCLUSION: Low-dose intravenous bolus IL-2 represents an effective regimen for the treatment of metastatic RCC, with preliminary results comparable to those observed with high-dose IL-2. Low-dose IL-2 can be administered with significantly fewer complications, reduced use of vasopressor support, and fewer admissions to an intensive care unit (ICU).
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. F. McDermott Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s. [Abstract] [Full Text] [PDF]

				D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, et al. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., January 1, 2005; 23(1): 133 - 141. [Abstract] [Full Text] [PDF]

				M. Aklilu, W. M. Stadler, M. Markiewicz, N. J. Vogelzang, M. Mahowald, M. Johnson, and T. F. Gajewski Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma Ann. Onc., July 1, 2004; 15(7): 1109 - 1114. [Abstract] [Full Text] [PDF]

				J.-M. Tourani, C. Pfister, N. Tubiana, M. Ouldkaci, G. Prevot, V. Lucas, S. Oudard, M. Malet, P. Cottu, J.-M. Ferrero, et al. Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group J. Clin. Oncol., November 1, 2003; 21(21): 3987 - 3994. [Abstract] [Full Text] [PDF]

				R. K. Strair, D. Schaar, D. Medina, M. B. Todd, J. Aisner, R. S. DiPaola, J. Manago, B. Knox, A. Jenkinson, R. Senzon, et al. Antineoplastic Effects of Partially HLA-Matched Irradiated Blood Mononuclear Cells in Patients With Renal Cell Carcinoma J. Clin. Oncol., October 15, 2003; 21(20): 3785 - 3791. [Abstract] [Full Text] [PDF]

				J. C. Yang, R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, D. E. White, et al. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3127 - 3132. [Abstract] [Full Text] [PDF]

				J. I. Clark, T. M. Kuzel, T. M. Lestingi, S. G. Fisher, P. Sorokin, B. Martone, M. Viola, and J. A. Sosman A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon {alpha}-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population Ann. Onc., April 1, 2002; 13(4): 606 - 613. [Abstract] [Full Text] [PDF]

				M. B. Atkins, B. Redman, J. Mier, J. Gollob, J. Weber, J. Sosman, B. L MacPherson, and T. Plasse A Phase I Study of CNI-1493, an Inhibitor of Cytokine Release, in Combination with High-Dose Interleukin-2 in Patients with Renal Cancer and Melanoma Clin. Cancer Res., March 1, 2001; 7(3): 486 - 492. [Abstract] [Full Text]

				J. P. Dutcher, T. Logan, M. Gordon, J. Sosman, G. Weiss, K. Margolin, T. Plasse, J. Mier, M. Lotze, J. Clark, et al. Phase II Trial of Interleukin 2, Interferon {{alpha}}, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study Clin. Cancer Res., September 1, 2000; 6(9): 3442 - 3450. [Abstract] [Full Text]

				G. C. de Gast, H.-J. Klümpen, F. A. Vyth-Dreese, M.-J. Kersten, N. C. V. Verra, J. Sein, D. Batchelor, W. J. Nooijen, and J. H. Schornagel Phase I Trial of Combined Immunotherapy with Subcutaneous Granulocyte Macrophage Colony-stimulating Factor, Low-Dose Interleukin 2, and Interferon {{alpha}} in Progressive Metastatic Melanoma and Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1267 - 1272. [Abstract] [Full Text]

				J. I. Clark, E. R. Gaynor, B. Martone, S. C. Budds, R. Manjunath, R. C. Flanigan, W. B. Waters, and J. A. Sosman Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-{{alpha}} in Patients with Advanced Renal Cell Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2374 - 2380. [Abstract] [Full Text] [PDF]

				R. A. Figlin, J. A. Thompson, R. M. Bukowski, N. J. Vogelzang, A. C. Novick, P. Lange, G. D. Steinberg, and A. S. Belldegrun Multicenter, Randomized, Phase III Trial of CD8+ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2521 - 2521. [Abstract] [Full Text] [PDF]

				M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 J. Clin. Oncol., July 1, 1999; 17(7): 2105 - 2105. [Abstract] [Full Text] [PDF]

				T. Cangiano, J. Liao, J. Naitoh, F. Dorey, R. Figlin, and A. Belldegrun Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy J. Clin. Oncol., February 1, 1999; 17(2): 523 - 523. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr Rational Therapy for Cutaneous T-Cell Lymphomas in the 1990s: Fact or Fancy? Arch Dermatol, May 1, 1995; 131(5): 603 - 605. [Abstract] [PDF]